CClinicalTrials.gg
Not yet recruitingNCT07499492TEXTUpdated Jul 10, 2026

Red Blood Cell Transfusion to Optimize Extubation

An interventional study of Transfusion of a single unit of RBC and standard of care in RBCs Transfusion in Critically-ill Patients, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In comparison with a liberal transfusion strategy (high haemoglobin threshold), a restrictive transfusion strategy leads to around 50% decrease in the total number of transfused red blood cells (RBC) units and 30% to 40% fewer transfused patients, without any difference in mortality. However, the optimal transfusion strategy where RBC benefits outweigh the risk of both anaemia and RBC transfusion), that depends on patients comorbidities and conditions, is likely to change over the stay in intensive care. Ventilator liberation is one of those clinical states with an increase in oxygen consumption. Low haemoglobin at the time of extubation has been identified to be associated with an increased risk of reintubation. The rate of reintubation has decreased over the last decades thanks to the development of post extubation strategies; however, reintubation remains a dreaded event associated with an increased morbidity and mortality.

The hypothesis is that a single unit of RBC transfused at the time of extubation would increase the success of extubation defined by survival without reintubation at day 7.

02

Conditions studied

  • RBCs Transfusion in Critically-ill Patients

Keywords

  • Red blood cell
  • Extubation
  • Critically-ill patients
  • transfusion
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years
  • Duration of invasive mechanical ventilation prior to extubation ≥ 24h
  • Planned extubation after weaning trial success
  • Patients at high risk of reintubation having at least one of the following criteria: older than 65 years, underlying chronic cardiac disease (including: left ventricular ejection fraction ≤ 45%, documented ischemic cardiopathy, chronic supraventricular arrhythmia, history of cardiogenic pulmonary edema) or lung disease (including documented or suspected: chronic obstructive pulmonary disease, obesity-hypoventilation syndrome, or restrictive pulmonary disease)
  • Haemoglobin level between 7.5 and 9.5 g/dl in the previous 48 hours (with no active bleeding and no transfusion in the interval)
  • Express informed consent (oral) from the relatives or the patient himself, or emergency inclusion procedure in case of inability of patient or proxy relatives to give consent
  • Affiliated to social security

Exclusion criteria

Exclusion Criteria:

  • Acute coronary syndrome with ST elevation in the previous 4 weeks
  • Peripheral neuromuscular disease as reason for intubation (underlying myopathy or myasthenia gravis)
  • Known objection to the administration of human blood products
  • Active bleeding
  • Inclusion in another trial investigating RBC transfusion and/or erythropoietin/ and/or post extubation strategies
  • Do-not-reintubate order at time of extubation
  • Vulnerable persons, under the protection of justice
  • Persons deprived of their liberty by judicial or administrative decision
  • Persons under legal protection (guardianship, curatorship)
  • Pregnant or breast-feeding woman
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Expérimental group

    Patient will systematically receive a single unit of crossed match leukoreduced RBC within the 4 hours of randomization

    Other: Transfusion of a single unit of RBC and standard of care

  • No intervention
    Control group

    Patient will receive standard of care alone

Interventions

  • OtherTransfusion of a single unit of RBC and standard of care

    Patients randomized in the experimental group will systematically receive a single unit of crossed match leukoreduced RBC. Transfusion will be performed as soon as possible (and transfusion onset must occur within the 4 hours after randomization), but should not delay extubation. The 4 hours delay allowed for the transfusion of the RBC unit is compatible with ICU practices in participating centres (they usually transfuse within an hour, unless specific cases).

06

What researchers measure

Primary outcomes

  1. Rate of reintubation or death following planned extubation.

    Time frame: up to day-7

Secondary outcomes

  1. Reintubation

    Time frame: 48 hours, 72 hours and up to ICU discharge

  2. Acute respiratory failure following extubation

    Time frame: Up to day-7

  3. Cardiogenic pulmonary oedema following extubation

    Time frame: up to day-7

  4. Number of ventilatory support-free days following extubation

    Time frame: up to day-14

  5. Length of stay in ICU

    Time frame: up to day-60

  6. Length of hospital stay

    Time frame: up to day-60

  7. Mortality in ICU

    Time frame: at day 28 and at day 60

  8. Mortality in hospital,

    Time frame: at day 28 and at day 60

  9. Number of RBC transfused in ICU after randomization

    Time frame: up to day-60

  10. Number of RBC transfused in hospital after randomization

    Time frame: up to day 60

  11. Quality of life questionary

    European Quality of life five-dimensions five-level questionnaire (EQ-5D-5L)

    Time frame: at day-60

  12. Hospital-acquired bacteraemia in ICU

    Time frame: up to day-60

  13. Severe post transfusion allergic reaction

    Time frame: up to day-60

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07499492
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 7, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Samia BALOUL
Contact
samia.baloul@aphp.fr
0149813385
Armand MEKONSTO, MD, PhD
study chair · Assistance public Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion